MedPath

Clinical Trial News

Wegovy Demonstrates Potential to Reduce COVID-19 Mortality in Clinical Trial

  • A recent clinical trial indicates that Wegovy, a popular obesity drug, significantly reduces the risk of death from COVID-19 by 33%.
  • The study found that Wegovy's protective effect occurred rapidly, even before significant weight loss was achieved by participants.
  • Participants taking Wegovy also experienced a lower overall death rate from all causes, suggesting a broader impact on life expectancy for individuals with obesity.
  • Researchers emphasize that the randomized trial design provides strong evidence supporting Wegovy's potential benefits in mitigating COVID-19 mortality.

Retatrutide Shows Promise in Improving Lipid and Cardiovascular Risk Profile

  • Retatrutide, a triple GLP-1/GIP/glucagon receptor agonist, significantly reduced non-HDL-C by up to 26.9% at 48 weeks in a Phase II trial.
  • The study demonstrated that retatrutide reduced triglycerides and apoC-III levels by up to 40.6% and 38.0%, respectively, after 48 weeks of treatment.
  • Eli Lilly's retatrutide also decreased the number of total and highly atherogenic small LDL particles, improving the overall lipid profile.
  • Key opinion leaders suggest retatrutide could potentially replace tirzepatide in the long term, with projected sales reaching over $9 billion by 2033.

A Study of LY3437943 in Participants Who Have Obesity or Are Overweight

NCT04881760CompletedPhase 2
Eli Lilly and Company
Posted 5/20/2021

Experimental Gene Therapy Shows Promise for SPG50, Faces Funding Hurdles

  • An experimental gene therapy offers hope for children with SPG50, a rare and fatal neurological disorder, by potentially halting disease progression.
  • Initial results from a Phase 2 study show that the gene therapy has led to improved cognitive function and stabilization of the condition in treated children.
  • The clinical trial is facing a funding crisis, with approximately $1 million needed per patient, threatening access to the potentially life-saving treatment.
  • A dedicated parent, Terry Pirovolakis, initiated the trial after his own son was diagnosed, but now relies on fundraising to continue the research and treatment.

ABYSS Trial: No Significant Difference in Outcomes Between Continuing or Stopping Beta-Blockers Post-MI

  • The ABYSS trial investigated the impact of interrupting versus continuing beta-blocker treatment in post-myocardial infarction patients with preserved ejection fraction.
  • Results showed no significant difference in the composite primary outcome of death, nonfatal myocardial infarction, stroke, or cardiovascular hospitalization.
  • Hospitalization for cardiovascular causes was slightly higher in the interruption group, suggesting potential risks associated with discontinuing beta-blockers.
  • Experts recommend caution in interpreting these results and suggest waiting for ongoing trials before updating clinical guidelines.

NIH Funds $15.5 Million Network to Boost Clinical Trial Participation Among Nursing Home Residents

  • The NIH has granted $15.5 million to establish NEXT STEPs, a national network aimed at including more nursing home residents in clinical research.
  • NEXT STEPs will focus on prevention, therapeutics, and care interventions to improve the quality of life for individuals in nursing homes.
  • The initiative includes multidisciplinary researchers across nine states, fostering partnerships between researchers and nursing homes.
  • The network aims to address the underrepresentation of nursing home residents in clinical trials, enhancing the development of tailored medical therapies.

Dark Chocolate Improves Retinal Vessel Function in Healthy Adults

  • A randomized, crossover trial found that dark chocolate intake enhances retinal vessel functionality in healthy individuals.
  • The study used optical coherence tomography angiography (OCT-A) and dynamic vessel analysis (DVA) to assess retinal perfusion and vascular response.
  • Dark chocolate, containing 400mg of flavanols, led to improved retinal vascular response compared to milk chocolate.
  • These findings suggest a potential benefit of dark chocolate on ocular health by improving retinal microcirculation.

Chocolate Dynamic Vessel Analysis

NCT05227248CompletedNot Applicable
Querques Giuseppe
Posted 4/9/2021

Semaglutide Demonstrates Cardioprotective Benefits in Patients with Kidney Disease and Heart Conditions

  • Semaglutide reduces cardiovascular risk by 20% in overweight or obese individuals, according to a clinical trial presented at the European Association for the Study of Diabetes annual meeting.
  • In patients with kidney disease, semaglutide reduced the risk of heart problems by 31% and overall mortality by 33%, highlighting its potential in this high-risk population.
  • SELECT trial data indicates semaglutide lowers the odds of death from all causes and may protect against severe COVID-19 outcomes in obese or overweight individuals.
  • Semaglutide shows promise in improving heart failure symptoms, physical limitations, and exercise function, irrespective of weight loss, as indicated by the STEP-HFpEF program sub-studies.

Personalized Immunotherapy Trialed in Australia Shows Promise in Cancer Treatment

  • An Australian-first clinical trial is personalizing immunotherapy for two cancer patients in Perth, marking a significant step in individualized cancer treatment.
  • The therapy involves analyzing a patient's unique cancer mutations to create a vaccine that primes the immune system to target and destroy cancer cells.
  • This personalized approach aims to overcome the limitations of traditional cancer treatments by specifically targeting cancer cells while minimizing harm to healthy tissues.
  • Early results from the trial are promising, offering hope for more effective and less toxic cancer therapies in the future.

AstraZeneca Unveils Oral Small Molecule PCSK9 Inhibitor AZD0780

  • AstraZeneca has disclosed AZD0780, an orally bioavailable small molecule inhibitor targeting PCSK9, potentially offering a convenient alternative to injectable therapies.
  • The development of AZD0780 leverages structure-based design to optimize drug-like properties for enhanced efficacy and patient compliance.
  • AZD0780 represents a significant advancement in PCSK9 inhibition, addressing the need for accessible and convenient LDL-C lowering treatments.
  • This oral PCSK9 inhibitor could broaden the therapeutic landscape for hypercholesterolemia management, pending clinical trial outcomes.

Leading Cardiologist Deepak Bhatt Highlights Critical Challenges in Clinical Trial Interpretation

  • Dr. Deepak Bhatt, Director of Mount Sinai Heart, addressed key pitfalls in clinical trial interpretation at ESC Congress 2024, drawing from his extensive experience leading landmark cardiovascular trials.
  • Research indicates a significant 17-year gap between scientific discoveries and their implementation in real-world clinical practice, highlighting the need for better interpretation and translation of trial results.
  • As a senior TIMI investigator with over 275,000 citations, Dr. Bhatt's expertise spans major trials including REDUCE-IT, SCORED, and THEMIS, positioning him as a leading authority on trial methodology.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.